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SUMMARY
SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against
COVID-19. Here, we systematically mapped the functional and phenotypic landscape of SARS-CoV-2-spe-
cific T cell responses in unexposed individuals, exposed family members, and individuals with acute or
convalescent COVID-19. Acute-phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic
phenotype that correlated with various clinical markers of disease severity, whereas convalescent-phase
SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-likememory phenotype. Importantly,
SARS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and conva-
lescent individuals with a history of asymptomatic and mild COVID-19. Our collective dataset shows that
SARS-CoV-2 elicits broadly directed and functionally replete memory T cell responses, suggesting that nat-
ural exposure or infection may prevent recurrent episodes of severe COVID-19.
INTRODUCTION
The world changed in December 2019 with the emergence of a
new zoonotic pathogen, severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2), which causes a variety of clinical syn-
dromes collectively termed coronavirus disease 2019 (COVID-
19). At present, there is no vaccine against SARS-CoV-2, and
the excessive inflammation associated with severe COVID-19
can lead to respiratory failure, septic shock, and ultimately,
death (Guan et al., 2020; Wolfel et al., 2020; Wu and McGoogan,
2020). The overall mortality rate is 0.5%–3.5% (Guan et al., 2020;
Wolfel et al., 2020; Wu and McGoogan, 2020). However, most
people seem to be affected less severely and remain asymptom-
atic or develop only mild symptoms during COVID-19 (He et al.,
2020b;Wei et al., 2020; Yang et al., 2020). It will therefore be crit-
ical for public health reasons to determine whether people with
milder forms of COVID-19 develop robust immunity against
SARS-CoV-2.
Global efforts are currently underway to map the determi-
nants of immune protection against SARS-CoV-2. Recent data
have shown that SARS-CoV-2 infection generates near-com-
plete protection against rechallenge in rhesus macaques
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Figure 1. T Cell Perturbations in COVID-19
(A) Dot plots summarizing the absolute counts and relative frequencies of CD3+ (left), CD4+ (center), and CD8+ T cells (right) in healthy blood donors from 2020
(2020 BD ) and patients with acute moderate (AM ) or acute severe COVID-19 (AS). Each dot represents one donor. Data are shown as median ± IQR. *p < 0.05,
***p < 0.001. Kruskal-Wallis rank-sum test with Dunn’s post hoc test for multiple comparisons.
(B) Top: PCA plots showing the distribution and segregation of memory CD4+ and CD8+ T cells by group. Each dot represents one donor. Memory cells were
defined by exclusion of naive cells (CCR7+CD45RA+CD95!). Center: PCA plots showing the corresponding trajectories of keymarkers that influenced the group-
(legend continued on next page)
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(Chandrashekar et al., 2020), and similarly, there is limited evi-
dence of reinfection in humans with previously documented
COVID-19 (Kirkcaldy et al., 2020). Further work is therefore
required to define the mechanisms that underlie these observa-
tions and evaluate the durability of protective immune responses
elicited by primary infection with SARS-CoV-2. Most correlative
studies of immune protection against SARS-CoV-2 have
focused on induction of neutralizing antibodies (Hotez et al.,
2020; Robbiani et al., 2020; Seydoux et al., 2020; Wang et al.,
2020). However, antibody responses are not detectable in all pa-
tients, especially those with less severe forms of COVID-19
(Long et al., 2020; Mallapaty, 2020; Woloshin et al., 2020). Previ-
ous work has also shown that memory B cell responses tend to
be short lived after infection with SARS-CoV-1 (Channappanavar
et al., 2014; Tang et al., 2011). In contrast, memory T cell re-
sponses can persist for many years (Le Bert et al., 2020; Tang
et al., 2011; Yang et al., 2006) and, in mice, protect against lethal
challenge with SARS-CoV-1 (Channappanavar et al., 2014).
SARS-CoV-2-specific T cells have been identified in humans
(Grifoni et al., 2020; Ni et al., 2020). It has nonetheless remained
unclear to what extent various features of the T cell immune
response associate with serostatus and the clinical course of
COVID-19. To address this knowledge gap, we characterized
SARS-CoV-2-specific CD4+ and CD8+ T cells in outcome-
defined cohorts of donors (total n = 206) from Sweden, which
has experienced a more open spread of COVID-19 than many
other countries in Europe (Habib, 2020).
RESULTS
T Cell Perturbations in COVID-19
Our preliminary analyses showed that the absolute numbers and
relative frequencies of CD4+ and CD8+ T cells were unphysiolog-
ically low in patients with acute moderate or severe COVID-19
(Figures 1A, S1A, and S1B). This finding has been reported pre-
viously (He et al., 2020a; Liu et al., 2020). We then used a 29-co-
lor flow cytometry panel to assess the phenotypic landscape of
these immune perturbations in direct comparisons with healthy
blood donors and individuals who had recovered from mild
COVID-19 acquired early during the pandemic (February–March
2020). Cohort demographics are described in the STARMethods
section. None of these variables were associated with disease
severity. The following parameters were measured in each sam-
ple: viability, C-C chemokine receptor type 7 (CCR7), cluster of
differentiation 3 (CD3), CD4, CD8, CD14, CD19, CD25, CD27,
CD28, CD38, CD39, CD45RA, CD69, CD95, CD127, cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4), C-X-C chemokine
receptor type 5 (CXCR5), granzyme B, human leukocyte antigen
(HLA)-DR, Ki-67, lymphocyte activation gene 3 (LAG-3), pro-
grammed cell death protein 1 (PD-1), perforin, T cell factor 1
(TCF1), T cell immunoreceptor with immunoglobulin (Ig) and
ITIMdomains (TIGIT), T cell Ig andmucin domain-containing pro-
tein 3 (TIM-3), thymocyte selection-associated high-mobility
group box factor (TOX), and natural killer cell receptor 2B4.
Unbiased principal component analysis (PCA) revealed clear
segregation between memory T cells from patients with acute
moderate or severe COVID-19 and memory T cells from conva-
lescent individuals and healthy blood donors (Figure 1B), driven
largely by expression of CD38, CD69, Ki-67, and PD-1 in the
CD4+ compartment and expression of CD38, CD39, CD69,
CTLA-4, HLA-DR, Ki-67, LAG-3, and TIM-3 in theCD8+ compart-
ment (Figures 1B, 1C, and S1C).
To extend these findings, we concatenated all memory CD4+
T cells and all memory CD8+ T cells from healthy blood donors,
convalescent individuals, and patients with acute moderate or
severe COVID-19. Phenotypically related cells were identified
using the clustering algorithm PhenoGraph, and marker expres-
sion patterns were visualized using the dimensionality reduction
algorithm Uniform Manifold Approximation and Projection
(UMAP). Distinct topographical clusters were apparent in each
group (Figures 1D, S2A, and S2B). In particular, memory CD8+
T cells from patients with acute moderate or severe COVID-19
expressed a distinct cluster of markers associated with activa-
tion and the cell cycle, including CD38, HLA-DR, Ki-67, and
PD-1 (Figures 1D and S2A). A similar pattern was observed
among memory CD4+ T cells from patients with acute moderate
or severe COVID-19 (Figure S2B). These findings were
confirmed via manual gating of the flow cytometry data (Fig-
ure 1E). Correlative analyses further demonstrated that the acti-
vated/cycling phenotype was strongly associated with SARS-
CoV-2-specific IgG levels and various clinical parameters,
including age, hemoglobin concentration, platelet count, and
plasma levels of alanine aminotransferase, albumin, D-dimer,
fibrinogen, and myoglobin (Figures S2C and S2D), but less
strongly associated with plasma levels of various inflammatory
markers, including interleukin (IL)-1b, IL-10, and tumor necrosis
factor (TNF) (Table S1).
Phenotypic Characteristics of SARS-CoV-2-Specific T
Cells in Acute and Convalescent COVID-19
Unphysiologically high expression frequencies of CD38, poten-
tially driven by a highly inflammatory environment, were
defined segregation of memory CD4+ and CD8+ T cells. Bottom: dot plots showing the group-defined distribution of markers in PC2. Each dot represents one
donor. MC, individuals in the convalescent phase after mild COVID-19. **p < 0.01, ***p < 0.001. Kruskal-Wallis rank-sum test with Dunn’s post hoc test for multiple
comparisons.
(C) Dot plots summarizing the expression frequencies of activation/cycling markers among memory CD4+ (top) and CD8+ T cells (bottom) by group. Each dot
represents one donor. Data are shown as median ± IQR. *p < 0.05, **p < 0.01, ***p < 0.001. Kruskal-Wallis rank-sum test with Dunn’s post hoc test for multiple
comparisons.
(D) Top: UMAP plots showing the clustering of memory CD8+ T cells by group in relation to all memory CD8+ T cells (left). Bottom: UMAP plots showing the
expression of individual markers (n = 3 donors per group). UMAP plots were based on all markers distinguished in the bottom row.
(E) Left: representative flow cytometry plots showing the expression of activation/cycling markers among memory CD8+ T cells by group. Numbers indicate
percentages in the drawn gates. Right: dot plots showing the expression frequencies of activation/cycling markers among memory CD8+ T cells by group. Each
dot represents one donor. Data are shown as median ± IQR. Key as in (B) and (C). **p < 0.01, ***p < 0.001. Kruskal-Wallis rank-sum test with Dunn’s post hoc test
for multiple comparisons.
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observed consistently among memory CD8+ T cells from pa-
tients with acute moderate or severe COVID-19 (Figures S3A
and S3B). In line with these data, we found that CD8+ T cells spe-
cific for cytomegalovirus (CMV) or Epstein-Barr virus (EBV) more
commonly expressed CD38, but not HLA-DR, Ki-67, or PD-1, in
patients with acute moderate or severe COVID-19 compared
with convalescent individuals and healthy blood donors, indi-
cating limited bystander activation and proliferation during the
early phase of infection with SARS-CoV-2 (Figures 2A, 2B, and
S3C). Of note, actively proliferating CD8+ T cells, defined by
expression of Ki-67, exhibited a predominant CCR7! CD27+
CD28+ CD45RA! CD127! phenotype in patients with acute
moderate or severe COVID-19 (Figure S3D), as reported previ-
ously in the context of vaccination and other viral infections (Bug-
gert et al., 2018; Miller et al., 2008). On the basis of these find-
ings, we used overlapping peptides spanning the immunogenic
domains of the SARS-CoV-2 spike, membrane, and nucleo-
capsid proteins to stimulate peripheral blood mononuclear cells
(PBMCs) from patients with acute moderate or severe COVID-
19. A vast majority of responding CD4+ and CD8+ T cells dis-
played an activated/cycling (CD38+ HLA-DR+ Ki67+ PD-1+)
phenotype (Figure 2C). These results were confirmed using an
activation-induced marker (AIM) assay to measure upregulation
of CD69 and 4-1BB (CD137), suggesting that most CD38+ PD-1+
CD8+ T cells were specific for SARS-CoV-2 (Figure 2D).
In further experiments, we used HLA class I tetramers as
probes to detect CD8+ T cells specific for the predicted optimal
epitopes fromSARS-CoV-2 (Figure S3E; Table S2). A vastmajor-
ity of tetramer+ CD8+ T cells in the acute phase of infection, but
not during convalescence, displayed an activated/cycling
phenotype (Figure 2E). In general, early SARS-CoV-2-specific
CD8+ T cell populations were characterized by expression of im-
mune activation molecules (CD38, HLA-DR, and Ki-67), inhibi-
tory receptors (PD-1 and TIM-3), and cytotoxic molecules
(granzyme B and perforin), whereas convalescent-phase
SARS-CoV-2-specific CD8+ T cell populations were skewed to-
ward an early differentiated memory (CCR7+ CD127+ CD45RA!/+
TCF1+) phenotype (Figure 2F). Importantly, the expression fre-
quencies of CCR7 and CD45RA among SARS-CoV-2-specific
CD8+ T cells were positively correlated with the number of symp-
tom-free days after infection (CCR7: r = 0.79, p = 0.001; CD45RA:
r = 0.70, p = 0.008), whereas the expression frequency of gran-
zyme B among SARS-CoV-2-specific CD8+ T cells was inversely
correlated with the number of symptom-free days after infection
(r = 0.70, p = 0.007) (Figure 2G). Time fromexposurewas therefore
associated with emergence of stem-like memory SARS-CoV-2-
specific CD8+ T cells.
Functional Characteristics of SARS-CoV-2-Specific T
Cells in Convalescent COVID-19
On the basis of these observations, we quantified functional
SARS-CoV-2-specific memory T cell responses across five
distinct cohorts, including healthy individuals who donated
blood before or during the pandemic, family members who
shared a household with convalescent individuals and were
exposed at the time of symptomatic disease, and individuals in
the convalescent phase after mild or severe COVID-19. We de-
tected potentially cross-reactive T cell responses directed
against the spike and/or membrane proteins in 28% of healthy
individuals who donated blood before the pandemic, consistent
with previous reports (Grifoni et al., 2020; Le Bert et al., 2020),
but nucleocapsid reactivity was notably absent in this cohort
(Figures 3A, S4A, and S4B). The highest response frequencies
against any of these three proteins were observed in convales-
cent individuals who experienced severe COVID-19 (100%). Pro-
gressively lower response frequencies were observed in conva-
lescent individuals with a history of mild COVID-19 (87%),
exposed family members (67%), and healthy individuals who
donated blood during the pandemic (46%) (Figure 3A).
To assess the functional capabilities of SARS-CoV-2-specific
memory CD4+ and CD8+ T cells in convalescent individuals, we
stimulated PBMCs with the overlapping spike, membrane, and
nucleocapsid peptide sets and measured a surrogate marker
of degranulation (CD107a) along with production of interferon
(IFN)-g, IL-2, and TNF (Figures 3B and 3C). SARS-CoV-2-spe-
cific CD4+ T cells predominantly expressed IFN-g, IL-2, and
TNF (Figure 3B), whereas SARS-CoV-2-specific CD8+ T cells
predominantly expressed IFN-g and mobilized CD107a (Fig-
ure 3C). We then used the AIM assay to determine the functional
polarization of SARS-CoV-2-specific CD4+ T cells. Interestingly,
spike-specific CD4+ T cells were skewed toward a circulating T
follicular helper (cTfh) profile, suggesting a key role in the gener-
ation of potent antibody responses, whereas membrane-spe-
cific and nucleocapsid-specific CD4+ T cells were skewed
toward a Th1 or a Th1/Th17 profile (Figures 3D, S5A, and S5B).
Antibody Responses and Proliferative Capabilities of
SARS-CoV-2-Specific T Cells in Convalescent COVID-19
In a final series of experiments, we assessed the recall capabil-
ities of SARS-CoV-2-specific CD4+ and CD8+ T cells in conva-
lescent individuals, exposed family members, and healthy blood
donors. Proliferative responses were identified by tracking the
progressive dilution of a cytoplasmic dye (CellTrace Violet
[CTV]) after stimulation with the overlapping spike, membrane,
and nucleocapsid peptide sets, and functional responses to
the same antigens were evaluated 5 days later by measuring
the production of IFN-g (Blom et al., 2013; Buggert et al.,
2014). Anamnestic responses in the CD4+ and CD8+ T cell com-
partments, quantified as a function of CTVlow IFN-g+ events (Fig-
ure 4A), were detected in most convalescent individuals (mild
COVID-19 [MC] = 96%, severe COVID-19 [SC] = 100%) and
exposed family members (92%) (Figures 4B and 4C). SARS-
CoV-2-specific CD4+ T cell responses were proportionately
larger overall than the corresponding SARS-CoV-2-specific
CD8+ T cell responses (exposed family members = 1.8-fold,
MC = 1.4-fold, SC = 1.8-fold) (Figure 4D). In addition, most
IFN-g+ SARS-CoV-2-specific CD4+ T cells produced TNF, and
most IFN-g+ SARS-CoV-2-specific CD8+ T cells expressed
granzyme B and perforin (Figure 4E).
Serological evaluations revealed a strong positive correlation
between IgG responses directed against the spike protein of
SARS-CoV-2 and IgG responses directed against the nucleo-
capsid protein of SARS-CoV-2 (r = 0.82, p < 0.001) (Figure S5C).
Moreover, SARS-CoV-2-specific CD4+ and CD8+ T cell re-
sponses were present in seronegative individuals, albeit at lower
frequencies compared with seropositive individuals (41% versus
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Figure 2. Phenotypic Characteristics of SARS-CoV-2-Specific T Cells in Acute and Convalescent COVID-19
(A and B) Dot plots summarizing the expression frequencies of activation/cycling markers among tetramer+ CMV-specific (A) or EBV-specific CD8+ T cells (B) by
group. Each dot represents one specificity in one donor. Data are shown as median ± IQR. *p < 0.05, **p < 0.01. Kruskal-Wallis rank-sum test with Dunn’s post
hoc test for multiple comparisons.
(C) Representative flow cytometry plots (left) and bar graphs (right) showing the expression of activation/cycling markers among CD107a+ and/or IFN-g+ SARS-
CoV-2-specific CD4+ and CD8+ T cells (n = 6 donors). Numbers indicate percentages in the drawn gates. Data are shown as median ± IQR. NC, negative control.
*p < 0.05, **p < 0.01. Paired t test or Wilcoxon signed-rank test.
(legend continued on next page)
ll
OPEN ACCESS
162 Cell 183, 158–168, October 1, 2020
Article
99%, respectively) (Figure 4F). These discordant responses
were nonetheless pronounced in some convalescent individuals
with a history of mild COVID-19 (3 of 31), exposed family mem-
bers (9 of 28), and healthy individuals who donated blood during
the pandemic (5 of 31) (Figures 4F and S5D), often targeting the
internal (nucleocapsid) and surface antigens (spike and/or mem-
brane) of SARS-CoV-2 (Figure 4G). Higher frequencies of SARS-
CoV-2-specific T cells were also found in exposed seronegative
family members compared with unexposed donors (Figure S5E).
Potent memory T cell responses were therefore elicited in the
absence or presence of circulating antibodies, consistent with
a non-redundant role as key determinants of immune protection
against COVID-19 (Chandrashekar et al., 2020).
DISCUSSION
We are currently facing the biggest global health emergency in
decades, namely the devastating outbreak of COVID-19. In the
absence of a protective vaccine, it will be critical to determine
whether exposed and/or infected people, especially those with
asymptomatic or very mild forms of the disease who likely act
inadvertently as major transmitters, develop robust adaptive im-
munity against SARS-CoV-2 (Long et al., 2020).
In this study, we used a systematic approach to map cellular
and humoral immune responses against SARS-CoV-2 in patients
with acute moderate or severe COVID-19, individuals in the
convalescent phase after mild or severe COVID-19, exposed
family members, and healthy individuals who donated blood
before (2019) or during the pandemic (2020). Individuals in the
convalescent phase after mild COVID-19 were traced after re-
turning to Sweden from endemic areas (mostly northern Italy).
These donors exhibited robust memory T cell responses months
after infection, even in the absence of detectable circulating an-
tibodies specific for SARS-CoV-2, that may contribute to protec-
tion against severe COVID-19.
We found that T cell activation, characterized by expression of
CD38, was a hallmark of acute COVID-19. Similar findings have
been reported previously in the absence of specificity data
(Huang et al., 2020; Thevarajan et al., 2020; Wilk et al., 2020).
Many of these T cells also expressed HLA-DR, Ki-67, and
PD-1, indicating a combined activation/cycling phenotype,
which correlated with early SARS-CoV-2-specific IgG levels
and, to a lesser extent, plasma levels of various inflammatory
markers. Our data also showed that many activated/cycling
T cells in the acute phase were functionally replete and specific
for SARS-CoV-2. Equivalent functional profiles have been
observed early after immunization with successful vaccines
(Blom et al., 2013; Miller et al., 2008; Precopio et al., 2007).
Accordingly, the expression of multiple inhibitory receptors,
including PD-1, likely indicates early activation rather than
exhaustion (Zheng et al., 2020a, 2020b).
Virus-specific memory T cells have been shown to persist for
many years after infection with SARS-CoV-1 (Le Bert et al.,
2020; Tang et al., 2011; Yang et al., 2006). In line with these ob-
servations, we found that SARS-CoV-2-specific T cells acquired
an early differentiated memory (CCR7+ CD127+ CD45RA!/+
TCF1+) phenotype in the convalescent phase, as reported previ-
ously in the context of other viral infections and successful vac-
cines (Blom et al., 2013; Demkowicz et al., 1996; Fuertes Mar-
raco et al., 2015; Precopio et al., 2007). This phenotype has
been associated with stem-like properties (Betts et al., 2006;
Blom et al., 2013; Demkowicz et al., 1996; Fuertes Marraco
et al., 2015; Precopio et al., 2007). Accordingly, we found that
SARS-CoV-2-specific T cells generated anamnestic responses
to cognate antigens in the convalescent phase, characterized
by extensive proliferation and polyfunctionality. Of particular
note, we detected similar memory T cell responses directed
against the internal (nucleocapsid) and surface proteins (mem-
brane and/or spike) in some individuals lacking detectable circu-
lating antibodies specific for SARS-CoV-2. Indeed, almost twice
as many healthy individuals who donated blood during the
pandemic had memory T cell responses versus antibody re-
sponses, implying that seroprevalence as an indicator may un-
derestimate the extent of adaptive immune responses against
SARS-CoV-2.
Our study was cross-sectional in nature and limited in terms of
clinical follow-up and overall donor numbers in each outcome-
defined group. It therefore remains to be determined whether
robust memory T cell responses in the absence of detectable
circulating antibodies can protect against severe forms of
COVID-19. This scenario has nonetheless been inferred from
previous studies of MERS and SARS-CoV-1 (Channappanavar
et al., 2014; Li et al., 2008; Zhao et al., 2016, 2017), both of which
have been shown to induce potent memory T cell responses that
persist for years, in contrast to the corresponding antibody re-
sponses (Alshukairi et al., 2016; Shin et al., 2019; Tang et al.,
2011). Antibody responses have also been shown to wane after
infection with SARS-CoV-2 (Ibarrondo et al., 2020; Long et al.,
2020), suggesting that transient humoral immunity is a general
feature of coronavirus infections (Callow et al., 1990). However,
the fact that memory B cells (Juno et al., 2020) and memory T
cells are generated in response to SARS-CoV-2 suggests that
natural infection may elicit protection from severe COVID-19.
In line with these observations, none of the convalescent individ-
uals in this study, including those with previous mild disease,
experienced further episodes of COVID-19.
(D) Representative flow cytometry plots (left) and bar graph (right) showing the upregulation of CD69 and 4-1BB (AIM assay) among CD38+ PD-1+ SARS-CoV-2-
specific CD8+ T cells (n = 6 donors). Numbers indicate percentages in the drawn gates. S, spike; M, membrane; N, nucleocapsid.
(E) Left: representative flow cytometry plots showing the expression of activation/cycling markers among tetramer+ SARS-CoV-2-specific CD8+ T cells by group
(red) and by total frequency (black). Center: UMAP plot showing the clustering of memory CD8+ T cells. Right: UMAP plots showing the clustering of tetramer+
SARS-CoV-2-specific CD8+ T cells by group and the expression of individual markers (n = 2 donors).
(F) Dot plots summarizing the expression frequencies of all quantified markers among tetramer+ SARS-CoV-2-specific CD8+ T cells by group. Each dot rep-
resents combined specificities in one donor. Data are shown as median ± IQR.
(G) Bivariate plots showing the pairwise correlations between symptom-free days and the expression frequencies of CCR7, CD45RA, or granzyme B (GzmB).
Each dot represents combined specificities in one donor. Key as in (F). Spearman rank correlation.
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Figure 3. Functional Characteristics of SARS-CoV-2-Specific T Cells in Convalescent COVID-19
(A) Left: dot plots summarizing the frequencies of IFN-g-producing cells responding to overlapping peptides spanning the immunogenic domains of the SARS-
CoV-2 S, M, and N proteins by group (ELISpot assays). Each dot represents one donor. The dotted line indicates the cutoff for positive responses. Right: bar
graph showing the frequencies of IFN-g-producing cells responding to the internal (N) and surface antigens (M and/or S) of SARS-CoV-2 by group (ELISpot
assays). 2019 BD, healthy blood donors from 2019; Exp, exposed family members; SC, individuals in the convalescent phase after severe COVID-19; SFU, spot-
forming unit. *p < 0.05, **p < 0.01, ***p < 0.001. Kruskal-Wallis rank-sum test with Dunn’s post hoc test for multiple comparisons.
(B) and (C) Left: representative flow cytometry plots showing the functional profiles of SARS-CoV-2-specific CD4+ (B) and CD8+ T cells (C) from a convalescent
individual (group MC). Numbers indicate percentages in the drawn gates. Right: bar graphs and pie charts summarizing the distribution of individual functions
among SARS-CoV-2-specific CD4+ (B) and CD8+ T cells (C) from convalescent individuals in groups MC (n = 12) or SC (n = 14). Data are shown as median ± IQR.
Key as in (A). *p < 0.05. Unpaired t test or Mann-Whitney U test.
(D) Left: bar graphs summarizing the functional polarization of SARS-CoV-2-specific CD4+ T cells from convalescent individuals in groups MC (n = 5) and SC (n =
6). Subsets were defined as CXCR5+ (cTfh), CCR4! CCR6! CXCR3+ CXCR5! (Th1), CCR4+ CCR6! CXCR3! CXCR5! (Th2), CCR4! CCR6+ CXCR3! CXCR5!
(Th17), CCR4!CCR6+ CXCR3+ CXCR5! (Th1/17), and CCR4!CCR6!CXCR3!CXCR5! (non-Th1/2/17). Data are shown as median ± IQR. *p < 0.05. Unpaired t
test orMann-WhitneyU test. Right: line graph comparing cTfh versus Th1 polarization by specificity in convalescent individuals from groupsMCandSC. Each dot
represents one donor. Key as in (A). *p < 0.05, **p < 0.01. Paired t test.
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Of note, we detected cross-reactive T cell responses directed
against the spike and/or membrane proteins of SARS-CoV-2 in
28% of unexposed healthy blood donors, consistent with a
high degree of pre-existing immunity in the general population
(Braun et al., 2020; Grifoni et al., 2020; Le Bert et al., 2020).More-
over, these particular data were derived from cryopreserved
samples, so this figuremight be considered as a lower bound es-
timate of overall prevalence (Owen et al., 2007). In this context,
our findings most likely reflect widespread exposure to seasonal
coronaviruses, which could shape the subsequent immune
response to SARS-CoV-2. As such, it remains likely that a frac-
tion of the anamnestic SARS-CoV-2-specific T cell response
was initially induced by seasonal coronaviruses in seronegative
individuals (Mateus et al., 2020). It is also tempting to speculate
that such responses may provide at least partial protection
against SARS-CoV-2, given that pre-existing T cell immunity
has been associated with beneficial outcomes after challenge
with the pandemic influenza virus strain H1N1 (Sridhar et al.,
2013; Wilkinson et al., 2012).
Collectively, our data provide a functional and phenotypicmap
of SARS-CoV-2-specific T cell immunity across the full spectrum
of exposure, infection, and disease. The observation that many
individuals with asymptomatic or mild COVID-19 had highly du-
rable and functionally replete memory T cell responses, not un-
commonly in the absence of detectable humoral responses,
further suggests that natural exposure or infection could prevent
recurrent episodes of severe COVID-19.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
1G1 (PE) [anti-CCR4] BD Biosciences 551120 (RRID:AB_394054)
11A9 (PE-Cy7) [anti-CCR6] BD Biosciences 560620 (RRID:AB_1727440)
RPA-T8 or UCHT1 (BUV805) [anti-CD3] BD Biosciences 565515 (RRID:AB_2739277)
RPA-T8 (BUV395) [anti-CD8] BD Biosciences 563795 (RRID:AB_2722501)
M-A251 (PE-Cy5) [anti-CD25] BD Biosciences 560988 (RRID:AB_2033955)
CD28.2 (BUV563) [anti-CD28] BD Biosciences 564438 (RRID:AB_2738808)
HIT2 (BUV496) [anti-CD38] BD Biosciences 564657 (RRID:AB_2744376)
FN50 (BV750) [anti-CD69] BD Biosciences 563835 (RRID:AB_2738442)
FN50 (BUV737) [anti-CD69] BD Biosciences 564439 (RRID:AB_2722502)
DX2 (BB630) [anti-CD95] BD Biosciences Custom conjugate
H4A3 (PE-CF594) [anti-CD107a] BD Biosciences 562628 (RRID:AB_2737686)
BNI3 (BB755) [anti-CTLA-4] BD Biosciences 560938 (RRID:AB_2033942)
RF8B2 (APC-R700) [anti-CXCR5] BD Biosciences 565191 (RRID:AB_2739103)
GB11 (BB790) [anti-granzyme B] BD Biosciences Custom conjugate
G46-6 (BUV615) [anti-HLA-DR] BD Biosciences 565073 (RRID:AB_2722500)
MQ1-17H12 (APC-R700) [anti-IL-2] BD Biosciences 565136 (RRID:AB_2739079)
B56 (BB660) [anti-Ki-67] BD Biosciences Custom conjugate
T47-530 (BUV661) [anti-LAG-3] BD Biosciences Custom conjugate
dG9 (BB700) [anti-perforin] BD Biosciences Custom conjugate
741182 (BUV737) [anti-TIGIT] BD Biosciences Custom conjugate
C1.7 (PE/Dazzle 594) [anti-2B4] BioLegend 393506 (RRID:AB_2734464)
G043H7 (APC-Cy7) [anti-CCR7] BioLegend 353211 (RRID:AB_10915272)
M5E2 (BV510) [anti-CD14] BioLegend 301842 (RRID:AB_2561946)
HIB19 (BV510) [anti-CD19] BioLegend 302242 (RRID:AB_2561668)
O323 (BV785) [anti-CD27] BioLegend 302832 (RRID:AB_2562674)
A1 (BV711) [anti-CD39] BioLegend 328227 (RRID:AB_2632893)
HI100 (BV421) [anti-CD45RA] BioLegend 304129 (RRID:AB_10900421)
HI100 (BV570) [anti-CD45RA] BioLegend 304131 (RRID:AB_10897946)
A019D5 (BV605) [anti-CD127] BioLegend 351334 (RRID:AB_2562022)
G025H7 (AF647) [anti-CXCR3] BioLegend 353712 (RRID:AB_10962948)
4S.B3 (BV785) [anti-IFN-g] BioLegend 502542 (RRID:AB_2563882)
EH12.2H7 (PE-Cy7) [anti-PD-1] BioLegend 367415 (RRID:AB_2616743)
F38-2E2 (BV650) [anti-TIM-3] BioLegend 345027 (RRID:AB_2565828)
Mab11 (BV650) [anti-TNF] BioLegend 502937 (RRID:AB_2561355)
4B41 (BV421) [anti-4-1BB] BioLegend 309820 (RRID:AB_2563830)
C63D9 (AF488) [anti-TCF1] Cell Signaling 6444 (RRID:AB_2797627)
REA473 (A647) [anti-TOX] Miltenyi Biotec 130-107-838 (RRID:AB_2654224)
S3.5 (PE-Cy5.5) [anti-CD4] Thermo Fisher Scientific MHCD0418 (RRID:AB_10376013)
eBio64DEC17 (PE) [anti-IL-17A] Thermo Fisher Scientific 12-7179-42 (RRID:AB_1724136)
Purified anti-CD28/CD49d BD Biosciences 347690 (RRID:AB_647457)
Ultra-LEAF OKT3 Purified [anti-CD3] BioLegend 317326 (RRID: AB_11150592)
LIVE/DEAD Fixable Aqua Dead Cell
Stain Kit
Thermo Fisher Scientific Cat#L34957
(Continued on next page)
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marcus
Buggert (marcus.buggert@ki.se)
Material Availability
HLA class I tetramers can be generated and shared on a collaborative basis.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Acute moderate blood samples Karolinska Hospital N/A
Acute severe blood samples Karolinska Hospital N/A
Mild convalescent blood samples Karolinska Hospital N/A
Severe convalescent blood samples Karolinska Hospital N/A
Exposed family member blood samples Karolinska Hospital N/A
2020 blood donor samples Karolinska Universitetslaboratoriet N/A
2019 blood donor samples Karolinska Universitetslaboratoriet N/A
Chemicals, Peptides, and Recombinant Proteins
Synthetic CMV peptides Peptides & Elephants GmbH https://www.peptides.de/
Synthetic EBV peptides Peptides & Elephants GmbH https://www.peptides.de/
Synthetic overlapping SARS-CoV-2
peptides (Prot_M, N, S)
Miltenyi Biotec https://www.miltenyibiotec.com/SE-en/
Optimal SARS-CoV-2 peptides Peptides & Elephants GmbH https://www.peptides.de/
Foxp3/TF Staining Buffer Set Invitrogen Cat#00-5523-00
Staphylococcal Enterotoxin B (SEB) Sigma-Aldrich Cat#S4881
Brefeldin A BioLegend Cat#420601
BD GolgiStop (with Monensin) BD Biosciences Cat#554724
BCIP/NBT Substrate Mabtech Cat#3650-10
BL21(DE3)pLysS Competent Cells Novagen Cat#69451
Triton X-100 Buffer Sigma-Aldrich Cat#X100
8M Urea Buffer Sigma-Aldrich Cat#51457
Cysteamine Sigma-Aldrich Cat#M9768
D-(+)-Biotin Sigma-Aldrich Cat#2031
Critical Commercial Assays
iFLASH Anti-SARS-CoV-2 IgG Kit YHLO Cat#20210217
LIAISON SARS-CoV-2 ELISA IgG Kit DiaSorin Cat#311450
Human IFN-g ELISpot Kit Mabtech Cat#3420-2A
BD Multitest 6-color TBNK reagent with BD
Trucount tubes
BD Biosciences Cat#337166
CellTrace Violet Cell Proliferation Kit Thermo Fisher Scientific Cat#C34571
Software and Algorithms
NetMHCpan EL 4.1 DTU Bioinformatics http://www.cbs.dtu.dk/services/
NetMHCpan-4.1/
FlowJo 10.6.1 FlowJo https://www.flowjo.com/
UMAP plugin 2.2 FlowJo https://www.flowjo.com/
GraphPad Prism 8.4.2 GraphPad Software https://www.graphpad.com/
PhenoGraph 0.2.1 PhenoGraph https://omictools.com/phenograph-tool
RStudio RStudio https://rstudio.com/
Python (scikit-learn 0.22.1) Python https://www.python.org/
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Data and Code Availability
The published article includes all data generated during this study. All codes are freely available at source.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Maximal disease severity was assessed using the NIH Ordinal Scale and Sequential Organ Failure Assessment (SOFA) (Beigel et al.,
2020; Singer et al., 2016). The NIH Ordinal Scale was defined as follows: (1) not hospitalized with no limitation of activities; (2) not
hospitalized with limitation of activities and/or home oxygen requirement; (3) hospitalized but not requiring supplemental oxygen
and no longer requiring ongoing medical care; (4) hospitalized and not requiring supplemental oxygen but requiring ongoing medical
care; (5) hospitalized requiring supplemental oxygen; (6) hospitalized requiring non-invasive ventilation or the use of high-flow oxygen
devices; (7) hospitalized receiving invasive mechanical ventilation or extracorporeal membrane oxygenation; and (8) death.
Donors were assigned to one of seven groups for the purposes of this study. AS: patients with acute severe disease requiring
hospitalization in the high dependency or intensive care unit, with low-flow oxygen support (< 10 L/min), high-flow oxygen support,
or invasive mechanical ventilation (n = 17). These patients had a median NIH Ordinal Scale score of 7 (IQR 6–7) and a median SOFA
score of 6 (IQR 3–6) at the time of sampling 12–17 days after disease onset (47%were viremic, and 82%were antibody-seropositive
for SARS-CoV-2). AM: patients with acute moderate disease requiring hospitalization and low-flow oxygen support (0–3 L/min;
n = 10). These patients had a median NIH Ordinal Scale score of 5 (IQR 5–5) and a median SOFA score of 1 (IQR 1–1) at the time
of sampling 11–14 days after disease onset (40% were viremic, and 50% were antibody-seropositive for SARS-CoV-2). SC: individ-
uals in the convalescent phase after severe disease (n = 26). Samples were collected 42–58 days after disease onset, corresponding
to 3–21 days after resolution of symptoms (100% were antibody-seropositive for SARS-CoV-2). MC: individuals in the convalescent
phase after mild disease (n = 40). Samples were collected 49–64 days after disease onset, corresponding to 25–53 days after
resolution of symptoms (85% were antibody-seropositive for SARS-CoV-2). Exp: family members who shared a household with
donors in groups MC or SC (n = 30). These individuals were exposed at the time of symptomatic disease (21% remained asymptom-
atic, and 63% were antibody-seropositive for SARS-CoV-2). 2020 BD: individuals who donated blood at the Karolinska University
Hospital in May 2020 (during the pandemic; n = 55). 2019 BD: individuals who donated blood at the Karolinska University Hospital
between July and September 2019 (before the pandemic; n = 28).
PBMCs were isolated from heparin-coated tubes (groups AS, AM, SC, MC, Exp, and 2020 BD) or citrate-anticoagulated buffy
coats (group 2019 BD). A separate serum separator tube was collected from each donor. All donors provided written informed
consent in accordance with the Declaration of Helsinki. The study was approved by the Swedish Ethical Review Authority. Donor
characteristics are summarized in Table S3, and immunological assay breakdowns are summarized in Table S4.
METHOD DETAILS
Flow cytometry
PBMCs were isolated from venous blood samples via standard density gradient centrifugation and used immediately (groups AS,
AM, SC, MC, Exp, and 2020 BD) or after cryopreservation in liquid nitrogen (group 2019 BD). Cells were washed in phosphate-buff-
ered saline (PBS) supplemented with 2% fetal bovine serum (FBS) and 2 mM EDTA (FACS buffer) and stained with PE-conjugated or
BV421-conjugated HLA class I tetramers and/or anti-CCR7–APC-Cy7 (clone G043H7; BioLegend) for 10 min at 37"C. Other surface
markers were detected via the subsequent addition of directly conjugated antibodies at pre-titrated concentrations for 20 min at
room temperature, and viable cells were identified by exclusion using a LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo Fisher
Scientific). Cells were thenwashed again in FACS buffer and fixed/permeabilized using a FoxP3 / Transcription Factor Staining Buffer
Set (eBioscience). Intracellular markers were detected via the addition of directly conjugated antibodies at pre-titrated concentra-
tions for 1 hr at 4"C. Stained cells were fixed in PBS containing 1% paraformaldehyde (PFA; Biotium) and stored at 4"C. Samples
were acquired using a FACSymphony A5 (BD Biosciences). Data were analyzed with FlowJo software version 10.6.1 (FlowJo
LLC). Gating strategies were described previously (Buggert et al., 2014, 2018). Core gates included singlet isolation (FSC-H versus
FSC-A), live CD3 selection (CD3 versus Aqua, CD14, and CD19), lymphocyte enrichment (SSC-A versus FSC-A), CD4 or CD8 selec-
tion (CD4 versus CD8). Detailed gating strategies for individual markers are depicted in the relevant figures.
Peptides
Peptides corresponding to known optimal epitopes derived from CMV (pp65) and EBV (BZLF1 and EBNA-1), overlapping peptides
spanning the immunogenic domains of the SARS-CoV-2 spike (Prot_S), membrane (Prot_M), and nucleocapsid proteins (Prot_N),
and optimal peptides for the manufacture of HLA class I tetramers were synthesized at > 95% purity. Lyophilized peptides were re-
constituted at a stock concentration of 10 mg/mL in DMSO and further diluted to 100 mg/mL in PBS.
Epitope prediction
Peptides were selected from full-length SARS-CoV-2 sequences spanning 82 different strains from 13 countries (National Center for
Biotechnology Information). The predicted binding affinities of conserved 9-mer peptides for HLA-A*0201 and HLA-B*0702 were
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determined using NetMHCpan version 4.1 (Reynisson et al., 2020). Binders were defined by a threshold IC50 value of 500 nM. Strong
binders were defined by a%Rank < 0.5, andweak binders were defined by a%Rank < 2 (Table S2). A total of 13 strong binders were
identified for tetramer generation (Table S2).
Tetramers
HLA class I tetramerswere generated as described previously (Price et al., 2005). Briefly, biotin-taggedHLA-A*0201 andHLA-B*0702
heavy chains were expressed under the control of a T7 promoter as insoluble inclusion bodies in Escherichia coli strain BL21(DE3)
pLysS (Novagen). IPTG-induced Escherichia coli were lyzed via repeated freeze/thaw cycles to release inclusion bodies that were
subsequently purified by washing in 0.5% Triton X-100 buffer (Sigma-Aldrich). Heavy chain and b2 m inclusion body preparations
were denatured separately in 8 M urea buffer (Sigma-Aldrich) and mixed at a 1:1 molar ratio. Each monomeric protein was refolded
in 2-mercaptoethylamine/cystamine redox buffer (Sigma-Aldrich) with the appropriate synthetic peptide (Peptides & Elephants
GmbH). Refolded monomers were purified via anion exchange after buffer replacement (10 mM Tris, pH 8.1). Purified monomers
were biotinylated using d-biotin and BirA (Sigma-Aldrich). Excess biotin was removed via gel filtration. Biotinylated monomers
were then tetramerized via the addition of fluorochrome-conjugated streptavidin at a 4:1 molar ratio, respectively. The following
specificities were used in this study: CMV A*0201 NV9 (NLVPMVATV), EBV A*0201 GL9 (GLCTLVAML), SARS-CoV-2 A*0201 AV9
(ALSKGVHFV), SARS-CoV-2 A*0201 HI9 (HLVDFQVTI), SARS-CoV-2 A*0201 KV9 (KLLEQWNLV), SARS-CoV-2 A*0201 LL9
(LLLDRLNQL), SARS-CoV-2 A*0201 LLY (LLYDANYFL), SARS-CoV-2 A*0201 SV9 (SLVKPSFYV), SARS-CoV-2 A*0201 TL9
(TLDSKTQSL), SARS-CoV-2 A*0201 VL9 (VLNDILSRL), SARS-CoV-2 A*0201 YL9 (YLQPRTFLL), SARS-CoV-2 B*0702 FI9
(FPRGQGVPI), SARS-CoV-2 B*0702 KT9 (KPRQKRTAT), SARS-CoV-2 B*0702 SA9 (SPRRARSVA), and SARS-CoV-2 B*0702 SL9
(SPRWYFYYL).
Functional assay
PBMCswere resuspended in complete medium (RPMI 1640 supplemented with 10%FBS, 1%L-glutamine, and 1%penicillin/strep-
tomycin) at 13 107 cells/mL and cultured at 13 106 cells/well in 96-well V-bottom plates (Corning) with the relevant peptides (each at
0.5 mg/mL) for 30 min prior to the addition of anti-CD28/CD49d (3 mL/mL; clone L293/L25; BD Biosciences), brefeldin A (1 mL/mL;
Sigma-Aldrich), monensin (0.7 mL/mL; BD Biosciences), and anti-CD107a–PE-CF594 (clone H4A3; BD Biosciences). Negative con-
trol wells lacked peptides, and positive control wells included staphylococcal enterotoxin B (SEB; 0.5 mg/mL; Sigma-Aldrich) or plate-
bound anti-CD3 (1 mg/mL; clone OKT3; BioLegend). Cells were analyzed by flow cytometry after incubation for 8 hr at 37"C.
Proliferation assay
PBMCs were labeled with CTV (0.5 mM; Thermo Fisher Scientific), resuspended in complete medium at 1 3 107 cells/mL, and
cultured at 1 3 106 cells/well in 96-well U-bottom plates (Corning) with the relevant peptides (each at 1 mg/mL) in the presence of
anti-CD28/CD49d (3 mL/mL; clone L293/L25; BD Biosciences) and IL-2 (10 IU/mL; PeproTech). Negative control wells lacked
peptides, and positive control wells included SEB (0.5 mg/mL; Sigma-Aldrich) or plate-bound anti-CD3 (1 mg/mL; clone OKT3;
BioLegend). Functional assays were performed as described above after incubation for 5 days at 37"C.
AIM assay
PBMCs were resuspended in complete medium at 1 3 107 cells/mL and cultured at 1 3 106 cells/well in 96-well U-bottom plates
(Corning) with the relevant peptides (each at 1 mg/mL) in the presence of anti-CD28/CD49d (3 mL/mL; clone L293/L25; BD
Biosciences). Cells were analyzed by flow cytometry after incubation for 24 hr at 37"C. The following directly conjugated monoclonal
antibodies were used to detect activation markers: anti-CD69–BUV737 (clone FN50; BD Biosciences) and anti-4-1BB–BV421 (clone
4B41; BioLegend).
Trucount
Absolute counts were obtained usingMultitest 6-color TBNK reagent with Trucount tubes (BDBiosciences). Samples were fixedwith
2%PFA for 2 hr prior to acquisition. Absolute CD3+ cell counts were calculated using the following formula: (# CD3+ events acquired x
total # beads x 1000) / (# beads acquired x volume of whole blood stained in mL). CD4+ and CD8+ cell counts were computed from the
respective frequencies relative to CD3+ cells.
Principal component analysis
Analyses were performed using scikit-learn version 0.22.1 in Python. Data were normalized using sklearn.preprocessing.
StandardScaler in the same package to generate z-scores for PCA.
UMAP
FCS 3.0 data files were imported into FlowJo software version 10.6.0 (FlowJo LLC). All samples were compensated electronically.
Dimensionality reduction was performed using the FlowJo plugin UMAP version 2.2 (FlowJo LLC). The downsample version 3.0.0
plugin and concatenation tool was used to visualize multiparametric data from up to a total of 120,000 CD8+ T cells (n = 3 donors
per group). Representative donors were selected from the 50th percentile for all markers. The following parameters were used in
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these analyses: metric = euclidean, nearest neighbors = 30, and minimum distance = 0.5. Clusters of phenotypically related cells
were detected using PhenoGraph version 0.2.1. The following markers were included in the cluster analysis: CCR7, CD27, CD28,
CD38, CD39, CD45RA, CD95, CD127, CTLA-4, CXCR5, granzyme B, Ki-67, LAG-3, PD-1, perforin, TCF1, TIGIT, TIM-3, TOX, and
2B4. Plots were generated using Prism version 8.2.0 (GraphPad Software Inc.).
ELISpot assay
PBMCswere rested overnight in completemedium and seeded at 23 105 cells/well in MultiScreen HTS Filter Plates (MerckMillipore)
pre-coated with anti-IFN-g (15 mg/mL; clone 1-D1K; Mabtech). Test wells were supplemented with overlapping peptides spanning
Prot_S, Prot_M, and Prot_N (each at 2 mg/mL; Miltenyi Biotec) or peptides corresponding to known optimal epitopes derived from
CMV (pp65) or EBV (BZLF1 and EBNA-1) (each at 2 mg/mL; Peptides & ElephantsGmbH). Negative control wells lacked peptides, and
positive control wells included SEB (0.5 mg/mL; Sigma-Aldrich). Assayswere incubated for 24 hr at 37"C. Plateswere thenwashed six
times with PBS (Sigma-Aldrich) and incubated for 2 hr at room temperature with biotinylated anti-IFN-g (1 mg/mL; clone mAb-7B6-1;
Mabtech). After six further washes, a 1:1,000 dilution of alkaline phosphatase-conjugated streptavidin (Mabtech) was added for 1 hr
at room temperature. Plates were then washed a further six times and developed for 20 min with BCIP/NBT Substrate (Mabtech). All
assays were performed in duplicate. Mean values from duplicate wells were used for data representation. Spots were counted using
an automated ELISpot Reader System (Autoimmun Diagnostika GmbH).
Serology
SARS-CoV-2-specific antibodies were detected in serum using both the iFLASH Anti-SARS-CoV-2 IgG chemiluminescent micropar-
ticle immunoassay against the nucleocapsid and spike proteins (Shenzhen YHLO Biotech Co. Ltd.) as well as the LIAISON
SARS-CoV-2 IgG fully automated indirect chemiluminescent immunoassay against the S1 and S2 (spike) proteins (DiaSorin). These
assays produced highly concordant results and have been shown to perform adequately as diagnostic tools (Plebani et al., 2020). An
individual was considered seropositive if one of the two methods generated a positive result. All assays were performed by trained
employees at the clinical laboratory according to standard procedures.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using R studio or Prism version 7.0 (GraphPad Software Inc.). Differences between unmatched
groups were compared using an unpaired t test, the Mann-Whitney U test, or the Kruskal-Wallis rank-sum test with Dunn’s post hoc
test for multiple comparisons, and differences betweenmatched groupswere compared using a paired t test or theWilcoxon signed-
rank test. Correlations were assessed using the Spearman rank correlation. Non-parametric tests were used if the data were not
distributed normally according to the Shapiro-Wilk normality test. Phenotypic relationships within multivariate datasets were
visualized using FlowJo software version 10.6.1 (FlowJo LLC).
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Figure S1. Quantification and Characterization of CD4+ and CD8+ T Cells in COVID-19, Related to Figure 1
(A) Flow cytometric gating strategy for the identification and quantification of CD4+ and CD8+ T cells. (B) Left: flow cytometric gating strategy for the identification
and quantification of memory CD4+ and CD8+ T cells. Right: dot plots summarizing the absolute numbers and relative frequencies of memory CD4+ and CD8+
T cells by group. Each dot represents one donor. Data are shown as median ± IQR. 2020 BD: healthy blood donors from 2020 (n = 18). AM: patients with acute
moderate COVID-19 (n = 11). AS: patients with acute severe COVID-19 (n = 17). (C) Dot plots summarizing the expression frequencies of phenotypic markers
amongmemory CD4+ and CD8+ T cells by group. Each dot represents one donor. Bars indicate median values. 2020 BD: healthy blood donors from 2020 (n = 18).
MC: individuals in the convalescent phase after mild COVID-19 (n = 31). AM: patients with acute moderate COVID-19 (n = 11). AS: patients with acute severe
COVID-19 (n = 17).
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Figure S2. Phenograph and UMAPClustering ofMemory CD4+ and CD8+ T Cells with Correlative Analyses of Immune Activation Phenotypes
versus Clinical Parameters in Acute COVID-19, Related to Figure 1
(A) Phenograph plots showing the clustering of memory CD8+ T cells and heatmap highlighting clusters 20 and 29. (B) Top left: UMAP plots showing the clustering
of memory CD4+ T cells by group in relation to all memory CD4+ T cells (left). Bottom left: UMAP plots showing the expression of individual markers (n = 3 donors
per group). Right: dot plots summarizing the expression frequencies of activation/cycling markers among memory CD4+ T cells by group. Each dot represents
one donor. Data are shown as median ± IQR. 2020 BD: healthy blood donors from 2020 (n = 18). MC: individuals in the convalescent phase after mild COVID-19
(n = 31). AM: patients with acute moderate COVID-19 (n = 11). AS: patients with acute severe COVID-19 (n = 17). *p < 0.05, **p < 0.01, ***p < 0.001. Kruskal-Wallis
rank-sum test with Dunn’s post hoc test for multiple comparisons. (C) and (D) Heatmaps summarizing the pairwise correlations between phenotypically defined
subpopulations of memory CD4+ or CD8+ T cells and various clinical parameters in patients with acute COVID-19. *p < 0.05, **p < 0.01, ***p < 0.001. Spearman
rank correlation.
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Figure S3. Immune Activation Patterns in Acute COVID-19, Related to Figure 2
(A) Representative flow cytometry plots showing the expression of activation/cycling markers among memory CD8+ T cells in patients with acute severe COVID-
19. Numbers indicate percentages in the drawn gates. (B) Top left: UMAP plots showing the clustering of memory CD8+ T cells by phenotype in relation to all
memory CD8+ T cells (left). Bottom left: UMAP plots showing the expression of individual markers (n = 1 donor per group). Right: dot plot summarizing the
frequencies of CD38+ HLA-DR!memory CD8+ T cells by group. Each dot represents one donor. Data are shown asmedian ± IQR. 2020 BD: healthy blood donors
from 2020 (n = 18). AM: patients with acute moderate COVID-19 (n = 11). AS: patients with acute severe COVID-19 (n = 17). ***p < 0.001. Kruskal-Wallis rank-sum
test with Dunn’s post hoc test for multiple comparisons. (C) Representative flow cytometry plots showing the expression of activation/cycling markers among
(legend continued on next page)
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CMV-specific memory CD8+ T cells in a healthy control and a patient with acute severe COVID-19. Numbers indicate percentages in the drawn gates. (D)
Representative flow cytometry plots showing the phenotype of Ki-67+ memory CD8+ T cells in a patient with acute severe COVID-19. Numbers indicate per-
centages in the drawn gates. (E) Left: representative flow cytometry plots showing SARS-CoV-2-specific tetramer+ CD8+ T cells in two donors from group MC.
Right: dot plot summarizing the frequencies of SARS-CoV-2-specific tetramer+ CD8+ T cells in donors from groups MC (n = 10) and SC (n = 2).
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Figure S4. Quantification of Functional T Cell Reactivity in COVID-19, Related to Figure 3
(A) Representative images showing the detection of IFN-g-producing cells responding to overlapping peptides spanning the immunogenic domains of the SARS-
CoV-2 spike (S), membrane (M), and nucleocapsid proteins (N) by group (ELISpot assays). NC: negative control. EBV: Epstein-Barr virus. CMV: cytomegalovirus.
SEB: staphylococcal enterotoxin B. (B) Dot plots summarizing the frequencies of IFN-g-producing cells responding to optimal peptide epitopes derived from EBV
BZLF1 and EBNA-1 (left) or CMV pp65 (right) by group (ELISpot assays). Each dot represents the mean of combined specificities in one donor. Bars indicate
median values. No significant differences were detected among groups for any specificity. 2019 BD: healthy blood donors from 2019 (n = 25). 2020 BD: healthy
blood donors from 2020 (n = 24). Exp: exposed family members (n = 30). MC: individuals in the convalescent phase after mild COVID-19 (n = 31). SC: individuals in
the convalescent phase after severe COVID-19 (n = 22). SFU: spot-forming unit.
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Figure S5. Functional Polarization of SARS-CoV-2-Specific Memory CD4+ T Cells, Antibody Correlations, and Comparative Analyses of
SARS-CoV-2-Specific CD4+ and CD8+ T Cell Responses versus Serostatus in COVID-19, Related to Figures 3 and 4
(A) Representative flow cytometry plots showing the identification of memory CD4+ T cells responding to overlapping peptides spanning the immunogenic
domains of the SARS-CoV-2 nucleocapsid protein by subset (AIM assay). Subsets were defined as CXCR5+ (cTfh), CCR4! CCR6! CXCR3+ CXCR5! (Th1),
CCR4+ CCR6! CXCR3! CXCR5! (Th2), CCR4! CCR6+ CXCR3! CXCR5! (Th17), CCR4! CCR6+ CXCR3+ CXCR5! (Th1/17), and CCR4! CCR6! CXCR3!
CXCR5! (non-Th1/2/17). (B) Bar graphs summarizing the functional polarization of memory CXCR5+ (cTfh) CD4+ T cells responding to overlapping peptides
spanning the immunogenic domains of the SARS-CoV-2 spike (S), membrane (M), and nucleocapsid proteins (N). Data are shown as median ± IQR. Key as in C.
(C) Correlation between anti-spike (S) and anti-nucleocapsid (N) IgG levels. Each dot represents one donor. 2020 BD: healthy blood donors from 2020 (n = 31).
Exp: exposed family members (n = 28). MC: individuals in the convalescent phase after mild COVID-19 (n = 31). SC: individuals in the convalescent phase after
severe COVID-19 (n = 23). Spearman rank correlation. (D) Representative flow cytometry plots showing functional SARS-CoV-2-specific memory CD4+ T cell
responses in a seronegative convalescent donor (groupMC). Numbers indicate percentages in the drawn gates. NC: negative control. S: spike. M:membrane. N:
(legend continued on next page)
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nucleocapsid. (E) Dot plots summarizing SARS-CoV-2-specific CD4+ and CD8+ T cell responses versus serostatus in exposed family members (left) and in-
dividuals in the convalescent phase after mild COVID-19 (right). Each dot represents one donor. Data are shown as median ± IQR. S: spike. M: membrane. N:
nucleocapsid. *p < 0.05. Mann-Whitney U test. (F) Dot plots summarizing SARS-CoV-2-specific CD4+ and CD8+ T cell responses in exposed seronegative family
members and unexposed healthy blood donors (group 2019 BD). Each dot represents one donor. Data are shown as median ± IQR. *p < 0.05. Mann-Whitney
U test.
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